Earnouts, the deferred payments that tie part of a sale price to how the business performs after closing, appear in 24% of deals outside life sciences, up from 17% in the 2014 to 2022 period, according to the 2026 SRS Acquiom M&A Deal Terms Study. In the study's dataset of private-target deals, sellers received about 21% of the maximum earnout dollars on offer. Several Delaware decisions this year show that the outcome often turns on contract wording and on how the buyer ran the business during the measurement period.
The SRS Acquiom study, which draws on more than 4,000 deals closed through 2025, found that earnouts showed up in 24% of non-life-sciences deals last year. Historical norms were closer to 15%. The increase is sharpest where private equity is the buyer: 24% of deals with a U.S. private equity buyer included an earnout, compared with 13% in 2014 to 2022. In lower middle-market transactions (deals of $50 million or less), the figure is 30%.
One reason is straightforward. When buyer and seller disagree about the future, an earnout lets each side be right on its own terms. The seller gets a path to a higher price if projections hold, and the buyer pays less at closing if they do not. Where valuation gaps are wide, more buyers appear to be asking for that bridge.
The payout data deserves equal attention. In the study's dataset of private-target deals closed from 2021 to mid-2024, 59% produced some earnout payment, but sellers received only 21% of the aggregate maximum earnout potential. Among deals where the seller achieved any success, the typical result was about 50 cents on the dollar. In the lower middle market, the median was 43 cents. An earnout is a real source of value, but it is a contingent one, and a seller who counts the full face amount as part of the price is likely to be disappointed.
Because most large deals choose Delaware law, its courts shape how earnouts work in practice. Their 2026 decisions point in two directions at once: they will police a buyer that acts in bad faith, and they will hold a seller to the words it negotiated.
The most closely watched seller win is Fortis Advisors v. Krafton, decided by the Court of Chancery on March 16. Krafton had acquired Unknown Worlds Entertainment for $500 million upfront with up to $250 million in earnouts. After trial, the court found that Krafton breached the agreement by terminating three key employees and taking operational control, and that its stated reasons for doing so were pretextual and aimed at avoiding the earnout as a major game launch approached. The remedies were unusual: the CEO was reinstated with operational authority, and the earnout measurement period was extended by 258 days.
Two Superior Court decisions in February reached a similar place on thinner contracts. In Jiggy Puzzles v. Steelhead Acquisition, the agreement had no efforts clause, yet the court let the seller's implied covenant claim proceed to trial, citing internal talk of making "game time decisions" if earnout triggers were close, along with cuts to peak-season marketing. In Monica v. Delta Data Software, sellers alleged the buyer invoiced a customer before the cutoff and then told the customer the invoice would be voided, pushing payment past the measurement date. The court allowed a prevention-doctrine claim to continue. The implied covenant, a default rule that parties will not act to deprive each other of the deal's benefits, is a narrow protection, and revenue decline alone does not trigger it. The seller must show bad-faith intent.
The buyer side won too. In a case Carlyle announced in September, the Court of Chancery held a five-day trial in March before Vice Chancellor Lori Will on claims by the founder of Saama Technologies, which Carlyle acquired in 2021. According to a summary from Carlyle's counsel, the court found Carlyle's objection to the earnout payment substantively correct and made in good faith, and found that the founder's focus on hitting the earnout led him to pursue conduct that impaired the business. Carlyle was awarded $7.3 million on its counterclaim. The lesson runs both ways: sellers who push the business toward the metric at the expense of its health can lose the earnout and face liability.

None of these cases turned on a surprise. They turned on drafting, and drafting is a negotiation point sellers can win before signing. Reed Smith's review of the 2026 decisions emphasizes that Delaware courts generally enforce the specific language parties choose, whether that is a narrow milestone or broad buyer discretion, and that the implied covenant will not rewrite express terms.
Three areas matter most. The first is the metric. Revenue-based earnouts are harder for a buyer to manipulate through cost allocation than EBITDA-based ones, since EBITDA (earnings before interest, taxes, depreciation, and amortization) depends on accounting choices, overhead charges, and integration costs the buyer controls. The second is the operating covenant: whether the buyer must run the business consistent with past practice, maintain staffing and marketing levels, or refrain from shifting sales to other affiliates. The third is the remedy, including acceleration of the earnout if the buyer sells the business or breaches its covenants, and a right to extend the measurement period if the buyer interferes.
Reporting rights deserve attention as well. A seller who receives no regular financial information during the earnout period cannot tell whether the metric is on track or whether a dispute is coming until the final statement arrives.
For a seller comparing offers, the practical step is to separate the cash at closing from the contingent amount and to value each on its own terms. An offer with a lower headline and more cash at closing can be worth more than a higher headline that relies on a stretch target. A buyer's valuation team will discount a contingent payment for risk and time; the seller should do the same, using the payout data as a sanity check on the probability.
Buyers should consider the same data from the other direction. An earnout that sellers see as unreachable does not bridge the valuation gap; it only delays the argument. Targets that both sides regard as achievable, paired with clear measurement rules, produce fewer disputes.
Earnout prevalence has risen for several years, and the court decisions on efforts standards, which the SRS Acquiom study notes are beginning to influence non-life-sciences negotiations, will likely make buyers more careful about internal communications and sellers more insistent on explicit covenants. Appeals and further trial rulings in the coming quarters may refine how far the implied covenant reaches. Owners planning a sale in the next year should expect earnout proposals to come up and should enter the conversation with a view on structure, not only on size.
Earnouts are becoming a standard part of deal structure, but the data shows sellers collect roughly one dollar in five of the maximum on offer, and Delaware's 2026 decisions show that drafting decides disputes. Owners should value the cash at closing separately, negotiate the metric, covenants, and remedies before signing, and treat any earnout as a contingent payment priced at its probability.